<DOC>
	<DOCNO>NCT02972866</DOCNO>
	<brief_summary>This study evaluate non inferiority Eurofarma budesonide nasal spary x referral Astrazeneca budesonide . Half patient receive Eurofarma medication half patient receive Astrazeneca medication . There placebo group .</brief_summary>
	<brief_title>Clinical Study , Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg Treatment Alergic Rhinitis</brief_title>
	<detailed_description>Budesonide medicine already use register 20 year . Eurofarma intention collect data safety efficacy present local authority . This study draw treat patient persisntent rhinits moderate severe site localted locally Brasil .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Age ≥ 12 . 2 . History alergic persistent rhinitis moderate severe least 2 year . 3 . Proved alergic use PRICK RAST test . 4 . Nasal symptom ( NIS ) &gt; 3 nasal obstruction &gt; 1 . 5 . Indication nasal corticorteroids use.. 6 . Washout nasal corticorteroids 14 day . 7 . ICF . 1 . Other type rhinitis ; 2 . Asthma non control 3 . Use oral/injectable corticoid 30 day screen . 4. patient eligible complete diary . 5. patient alergy substance medicine . 6. non control desease .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>